Wire · opportunities
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The U.S. FDA granted accelerated approval to sevabertinib for treating adult patients with locally advanced or metastatic nonsquamous NSCLC with HER2 TKD activating mutations, including treatment-naive cases. This approval expands treatment options and is based on clinical trial results showing a 75% objective response rate.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new pathway to reach NSCLC patients with HER2 mutations who haven’t had prior therapy, expanding your addressable market. Competitors must reassess their pipeline timing against sevabertinib’s newly widened label.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics